Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp162 | Cushing's | ECE2019

Pharmacokinetics of osilodrostat following single and multiple doses of osilodrostat in healthy subjects and patients with Cushing’s disease

Han Kevin , Tauchmanova Libuse , Atkinson Susan , Darstein Christelle , Zhang Xinrui , Combes Francois Pierre , Pedroncelli Alberto M

Introduction: Osilodrostat is a potent oral 11β-hydroxylase inhibitor currently in Phase III clinical development for the treatment of Cushing’s syndrome (CS). The key pharmacokinetic (PK) properties, drug–drug interactions (DDIs), and population PK findings for osilodrostat in humans are summarized.Methods: Osilodrostat PK has been characterized in nine Phase I studies (healthy subjects and subjects with hepatic or renal impairment), two ...

ea0063p734 | Pituitary and Neuroendocrinology 2 | ECE2019

A phase 2 study assessing osilodrostat in children and adolescent patients with Cushing’s disease – Rationale and methods

Storr Helen L , Shah Nalini , Wojna Judi , Han Kevin , Roughton Michael , Pierre Combes Francois , Pultar Philippe , Savage Martin O

Background: In children, Cushing’s disease (CD) presents with a combination of weight gain and slowed linear growth. First-line pituitary surgery is the treatment of choice for most patients. In paediatric patients, the transsphenoidal surgical success rate is 60%–98% when performed by an expert pituitary surgeon. There is a need for additional pharmacological interventions to control hypercortisolaemia, which are currently limited, in children and adolescents. In ph...